Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
MedSIR
Bayer
Wake Forest University Health Sciences
City of Hope Medical Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Novartis
BicycleTx Limited
Astellas Pharma Inc
Nanobiotix
Massachusetts General Hospital
Lund University Hospital
Valo Therapeutics Oy
Virginia Commonwealth University
Cedars-Sinai Medical Center
Fox Chase Cancer Center
Cedars-Sinai Medical Center
University Health Network, Toronto
Providence Health & Services
Salubris Biotherapeutics Inc
Adlai Nortye Biopharma Co., Ltd.
University of Kansas Medical Center